RT Journal Article
T1 Safety data on in situ gelling bimatoprost loaded nanovesicular formulations
A1 Yadav, Monika
A1 Guzmán Aránguez, Ana Isabel
A1 Pérez de Lara, María Jesús
A1 Singh, Mandeep
A1 Singh, Joga
A1 Pal Kaur, Indu
AB In vitro cytotoxicity and in vivo acute and 7 days repeat-dose ocular toxicity studies, were conducted in rabbits, in accordance with the Organisation for Economic Co-operation and Development (OECD) guidelines, for bimatoprost loaded nanovesicular aqueous dispersion (BMT-NV) and its in-situ gelling sub-conjunctival implant (BMT-NV-IM). For details on the preparation and evaluation of BMT-NV and its BMT-NV-IM for the control of glaucoma, please refer to ‘Bimatoprost loaded nanovesicular long-acting sub-conjunctival in-situ gelling implant: In vitro and in vivo evaluation’ (Yadav et al., 2019). The in vivo ocular toxicity was performed only after confirming dermal safety, as required by OECD. Histological evaluation of various ocular tissues, following sub-conjunctival implantation with BMT-NV-IM, was done for ocular tolerance studies.
PB Elsevier
SN 2352-3409
YR 2019
FD 2019-08
LK https://hdl.handle.net/20.500.14352/13600
UL https://hdl.handle.net/20.500.14352/13600
LA eng
NO Received 10 May 2019, Revised 19 July 2019, Accepted 29 July 2019, Available online 6 August 2019.Refers to: Bimatoprost loaded nanovesicular long-acting sub-conjunctival in-situ gelling implant: In vitro and in vivo evaluation
DS Docta Complutense
RD 6 may 2024